Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Isabel Cunningham MD

Isabel Cunningham MD

Adjunct Associate Research Scientist, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, New York

With broad experience in both academic oncology and clinical research, Dr. Cunningham provides a crucial bridge between community and academic medicine. Dr. Cunningham received her AB from Bryn Mawr College and her MD from Yale University School of Medicine. Her postgraduate training included a fellowship in hematology-oncology and bone marrow transplant at Memorial Sloan-Kettering Cancer Center. Dr. Cunningham has held academic positions at Memorial Sloan-Kettering and several other universities, and she is currently conducting research at Columbia University. She has published extensively and has been a reviewer for Blood, Bone Marrow Transplantation, Experimental Hematology, and Leukemia & Lymphoma.

Positions:
Adjunct Associate Research Scientist, Columbia University

Degrees:
Bryn Mawr College, AB
Yale University School of Medicine, MD

Postgraduate Training:
Resident, Internal Medicine, Presbyterian Hospital, New York
Fellow, Hematology/Oncology, Memorial Sloan-Kettering Cancer Center

Board Certifications:
Internal medicine
Hematology

Clinical Interests:
Hematologic malignancies
Extramedullary Leukemia

Disclosures

Dr. Cunningham does not have any financial disclosures.

Recent Contributions to PracticeUpdate:

  1. Characteristics and Predictors of Early Hospital Deaths in Newly Diagnosed Acute Promyelocytic Leukemia
  2. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-Versus-Host Disease
  3. Durable Remissions Following Combined Targeted Therapy in Patients With CLL Harboring TP53 Deletions and/or Mutations
  4. ASCO 2021: Abstract Recommendations From Dr. Isabel Cunningham for Hematologic Malignancies
  5. Vemurafenib Plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
  6. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia
  7. Outcomes of Adults With B-ALL Progressing After CD19 CAR T-Cell Therapy
  8. Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia
  9. Ublituximab Plus Ibrutinib vs Ibrutinib Alone for Patients With Relapsed or Refractory High-Risk CLL
  10. Measurable Residual Disease Affects Allo-HCT in Ph+ Acute Lymphoblastic Leukemia

Most Read This Week

Recently Updated